1-6 of 6
Gary Meininger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680–1686

Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger
Journal: Diabetes Care
Diabetes Care 2016;39(1):e19
https://doi.org/10.2337/dci15-0026
Published: 14 December 2015
View article titled, Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680–1686
Open the PDF for Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680–1686 in another window
Journal Articles

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger
Journal: Diabetes Care
Diabetes Care 2015;38(9):1680–1686
https://doi.org/10.2337/dc15-1251
Published: 22 July 2015
View article titled, Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
Open the PDF for Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program in another window
Journal Articles

Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba, Joel Jiang, Frank Vercruysse, Gary Meininger, David Matthews, on behalf of the CANVAS Trial Collaborative Group
Journal: Diabetes Care
Diabetes Care 2015;38(3):403–411
https://doi.org/10.2337/dc14-1237
Published: 02 December 2014
View article titled, Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
Open the PDF for Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

Lawrence A. Leiter, Kun-Ho Yoon, Pablo Arias, Gisle Langslet, John Xie, Dainius A. Balis, Dawn Millington, Frank Vercruysse, William Canovatchel, Gary Meininger
Journal: Diabetes Care
Diabetes Care 2015;38(3):355–364
https://doi.org/10.2337/dc13-2762
Published: 09 September 2014
View article titled, Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study
Open the PDF for Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study in another window
Includes: Supplementary data
Journal Articles

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial

Guntram Schernthaner, MD, Jorge L. Gross, MD, Julio Rosenstock, MD, Michael Guarisco, MD, Min Fu, MS, Jacqueline Yee, MS, Masato Kawaguchi, MD, William Canovatchel, MD, Gary Meininger, MD
Journal: Diabetes Care
Diabetes Care 2013;36(9):2508–2515
https://doi.org/10.2337/dc12-2491
Published: 13 August 2013
View article titled, Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: <subtitle>A 52-week randomized trial</subtitle>
Open the PDF for Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: <subtitle>A 52-week randomized trial</subtitle> in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone

Bernard Charbonnel, MD, Avraham Karasik, MD, Ji Liu, MA, Mei Wu, MS, Gary Meininger, MD, for the Sitagliptin Study 020 Group
Journal: Diabetes Care
Diabetes Care 2006;29(12):2638–2643
https://doi.org/10.2337/dc06-0706
Published: 01 December 2006
View article titled, Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
Open the PDF for Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone in another window
Includes: Supplementary data